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Abstract Drug design is a process driven by innovation
and technological breakthroughs involving a combination of
advanced experimental and computational methods. A broad
variety of medicinal chemistry approaches can be used for
the identification of hits, generation of leads, as well as to
accelerate the optimization of leads into drug candidates.
Quantitative structure–activity relationship (QSAR) meth-
ods are among the most important strategies that can be
applied for the successful design of small molecule mod-
ulators having clinical utility. Hologram QSAR (HQSAR)
is a modern 2D fragment-based QSAR method that employs
specialized molecular fingerprints. HQSAR can be applied to
large data sets of compounds, as well as traditional-size sets,
being a versatile tool in drug design. The HQSAR approach
has evolved from a classical use in the generation of stan-
dard QSAR models for data correlation and prediction into
advanced drug design tools for virtual screening and phar-
macokinetic property prediction. This paper provides a brief
perspective on the evolution and current status of HQSAR,
highlighting present challenges and new opportunities in drug
design.
Keywords Drug design · SAR · QSAR · Fragment-based ·
Pharmacodynamics · Pharmacokinetics
L. B. Salum · A. D. Andricopulo (B)
Laboratório de Química Medicinal e Computacional, Centro de
Biotecnologia Molecular Estrutural, Instituto de Física de São
Carlos, Universidade de São Paulo, Av. Trabalhador São-Carlense 400,
13560-970 São Carlos, SP, Brazil
e-mail: aandrico@if.sc.usp.br
Introduction
The identification of promising hits and the generation of
high quality leads are crucial steps in the early stages of
drug discovery [1–3]. Advances in medicinal chemistry at
the interface of chemistry and biology have created an impor-
tant foundation in the search for new drug candidates pos-
sessing a combination of optimized pharmacodynamic and
pharmacokinetic properties. During the past decade, high-
performance hardware and sophisticated software, along with
advances in scientific knowledge, have evolved into core
components facilitating the rapid integration of many funda-
mental fields that drive pharmaceutical research and develop-
ment (R&D) [3–6]. These components have become
crucial differentiating factors, as observed in the rational
design of many bioactive molecules. The transformation is
evident across all areas of research and includes, but is not
limited to, structure and function determination of target
proteins, hit selection, lead optimization, development of
structure–activity relationships (SAR) and the design of new
chemical entities (NCEs) as therapeutic agents. Despite the
impact of recent technological and scientific advances, drug
discovery has become more expensive and time consuming
[7, 8].
One of the most important challenges for the pharmaceuti-
cal industry is the identification of innovative NCEs from an
incredibly large reservoir of real and virtual possible com-
pounds [6, 9, 10]. In the early stages of the process, small
molecule chemical libraries are screened for the identifica-
tion of new promising compounds. These libraries widely
vary in size and complexity, and have been used for a wide
range of drug targets in a variety of biochemical assays. This
process has been compared to finding a needle in a haystack,
where the needle is a promising hit or lead and the haystack
represents the complex multidimensional chemical space. In
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Fig. 1 From hit identification
to lead optimization and
candidate selection. SAR and
QSAR methods are essential
elements of this process
general, identification of a small selective fraction of com-
pounds with sufficient promise as hits for further optimiza-
tion is a major problem involved in this lengthy and risky
process. Although trial-and-error factor is inherent in drug
research, rational concepts are considered valuable tools for
the steps of lead selection and optimization. In drug discov-
ery hit identification, there is a clear paradigm shift from
the screening of random collections to a rational process,
which would directly affect the success rate of lead discovery
and optimization. The generation of focused libraries based
on promising bioactive molecules has revitalized the para-
digm of the screening process and raised enormous excite-
ment about the possibility of identifying new potential leads.
These new perspectives have highlighted the importance of
exploring the intrinsic complementary nature of classical
and modern methods in drug research [9, 11–13]. Data sets
of compounds sharing a high degree of chemical similarity
and still possessing interesting structural diversity have been
designed for a variety of specific purposes (e.g., optimization
of potency).
One of the main requirements for lead generation and
optimization is to maximize the range of structural types
within data sets, based on the expectation that new active
compounds will be identified. As a consequence, the under-
standing of the SARs is a cornerstone of classical and mod-
ern medicinal chemistry for all academic and industry drug
discovery projects [14, 15]. The rational design of exper-
iments for the generation of standard large-scale biologi-
cal data is a critical step, making possible comparisons of
predictions and experimental results. The high number of
hits that need to be optimized assure the utility of SAR
in drug design, leading to the generation of a variety of
data sets. When SARs can be quantitatively measured within
these data sets, they become quantitative structure–activ-
ity relationships (QSAR). QSAR is a valuable drug design
tool that applies statistical analysis of relationships between
chemical structure and biological activity in a quantitative
and mechanism-oriented manner [16–19]. QSAR technolo-
gies has been employed, and continue to be developed and
employed, both to correlate information in data sets and to
facilitate, for example, the discovery of enzyme inhibitors,
agonist or antagonists of important drug targets [20–24]. Fig-
ure 1 provides a flowchart for the process of hit identification
and lead optimization, showing the important role of SAR
and QSAR in drug design.
As shown in Fig. 1, 2D QSAR methods permit the inves-
tigation of a wide variety of biological properties for a high
number of compounds, including those cases when the 3D
structural information for the biological target is not avail-
able. In theses cases, fragment-based methods are especially
useful. One of such methods is hologram QSAR (HQSAR),
a fragment-based QSAR approach that has emerged as a pow-
erful tool to explore the chemical and biological space of data
sets of compounds. The aim of this perspective article is to
provide the reader with a brief insight of the current role
of HQSAR in drug design, highlighting the advances, chal-
lenges and future directions.
Fragment-based QSAR methods: hologram QSAR
(HQSAR)
HQSAR is a modern 2D QSAR approach based on special-
ized molecular fragments [25–27]. In HQSAR, each mol-
ecule in a training set is broken down into several unique
structural fragments which are arranged to form a molecular
hologram, an extended form of fingerprint that encodes all
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Fig. 2 Generation of molecular
holograms and HQSAR models
possible molecular fragments (e.g., linear, branched, cyclic,
overlapping). The molecular fingerprint additionally main-
tains a count of the frequency of the various molecular frag-
ment types in the bins of fixed length array using a pre-defined
set of rules derived from parameters that specify the size
and type of fragment substructures that are to be encoded.
A scheme for the generation of molecular holograms is
depicted in Fig. 2.
One important aspect is that the incorporation of informa-
tion about each fragment, and each of its constituent frag-
ments, implicitly encodes 3D structural information, such as
hybridization and chirality. With the transformation of the
chemical representation of a molecule into its correspond-
ing molecular hologram, this method requires no explicit 3D
information (e.g., determination of 3D structures, putative
binding conformations, and molecular structural alignment)
and avoids the calculation and selection of physicochemical
descriptors. The only requirements for HQSAR model gen-
eration are the 2D structures of the data set compounds and
the corresponding property values. As shown in Fig. 2, the
fragment patterns counts from the training set compounds
can be related to their corresponding experimental biologi-
cal parameters using partial least squares (PLS) analysis in
order to generate HQSAR models. The bin occupancies of
the molecular holograms are the structural descriptors (inde-
pendent variables) encoding the specific compositional and
topological molecular information. In general, biological or
pharmacological data (e.g., Ki , IC50, EC50) are converted
into negative logarithmic values (e.g., pKi , pIC50, pEC50,
respectively) and used as dependent variables in the QSAR
investigations [25–27]. HQSAR explains differences in the
observed activity in a series of molecules by quantifying vari-
ations within their calculated molecular holograms.
HQSAR: a versatile tool in drug design
Several HQSAR models for a variety of standard data sets
consisting of ligands of important molecular targets have
been generated throughout recent years [20, 21, 26–40],
including cases where the 3D structure of the target protein
was not yet available or the molecular target was unknown. It
is important to note that besides predicting accurately prop-
erty values of untested compounds (e.g., potency, affinity),
HQSAR models can also provide useful insights into the
relationships between structural fragments (micromolecule)
and biological activity [25]. These fragments can be easily
visualized through the generation of contribution maps that
reflect the individual contribution of each atom or structural
fragment in a given bioactive molecule of the data set. This
information, combined with synthetic and medicinal chem-
istry knowledge, could lead to the synthesis of new mole-
cules with improved properties. For example, this principle
can be applied to differentiate the 2D HQSAR contribu-
tion map for the most potent compound (IC50 = 10 nM) of
a large collection of 9-substituted-9-deazaguanine analogs
that inhibit human purine nucleoside phosphorylase (PNP)
enzyme (Fig. 3a) [20]. The contribution map allowed the
identification of key structural components essential for inter-
molecular interactions in the protein active site. The standard
HQSAR visual code uses colors at the red end of the spec-
trum (red, red orange, and orange) for poor contributions and
colors at the green end of the spectrum (yellow, green blue,
and green) for favorable contributions. Atoms or fragments
with intermediate contributions are colored white. Analyzing
the contribution map of Fig. 3a, it can be observed that the
molecular fragments for the purine ring and cyanil moieties
are strongly involved in the inhibitory profile of the
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Fig. 3 a 2D HQSAR
contribution map for the most
potent inhibitor of a set of PNP
ligands. b Representation of the
intermolecular interactions
implicated in the purine base
binding of the same inhibitor
(PDB ID 1B8O)
Fig. 4 Integration of HQSAR, CoMFA and molecular modeling methods in the design of ligands of ER. a HQSAR contribution map. b CoMFA
contour steric and electrostatic maps. c Predicted binding mode for the highest affinity ligand in the ER crystal structure (PDB ID: 1XP1)
compound as previously described [20]. Thus, it is possi-
ble to identify specific individual atomic contributions as
determinants of increased potency in the absence of the 3D
crystal structure of PNP or any other 3D structural informa-
tion. However, when 3D structural information is available,
this allows a comparison of the HQSAR results to determine
if they are in agreement with the 3D chemical environment
of the target protein (Fig. 3b) [20].
In a similar way to that of the PNP example, a series
of relevant HQSAR models have been generated for other
molecular targets (and distinct data sets) and used in con-
junction with classical or 3D QSAR methods, as well as
with molecular modeling. This optimized integration scheme
represents a valuable component for lead optimization and
an important strategy for drug design [20, 21, 27–30, 33, 36,
38–44].The information obtained from these complemen-
tary approaches has successfully allowed the incorporation
of additional features in the interpretation of HQSAR mod-
els in terms of their chemical and biological significance
[45].
As an illustrative example of the integration of QSAR
strategies, a study with a large series of flavanoids, dihydro-
benzoxathiins and dihydrobenzodithiins as estrogen recep-
tor (ER) modulators demonstrated that HQSAR and CoMFA
(comparative molecular field analysis) studies can be car-
ried out concomitantly to search for synergies between 2D
and 3D QSAR technologies [21]. The HQSAR contribution
map for the data set modulator having the highest binding
affinity (IC50 = 0.3 nM) for ER (Fig. 4a) shows that both the
hydroxyl aromatic groups and the protonated nitrogen of the
pyrrolidine ring are positive contributions to binding affinity.
The molecular fragments highlighted by the HQSAR model
are strongly correlated to the binding affinity of this series of
ligands, which is in accordance with the 3D QSAR CoMFA
results shown in the steric and electrostatic contour maps in
Fig. 4b. Here, the CoMFA electrostatic contour map shows
blue contours surrounding the protonated nitrogen atom in
the pyrrolidine ring, representing a region where the elec-
tropositive environment correlates directly to higher binding
affinity. On the other hand, the steric contour maps show a
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Fig. 5 Three-dimensional
model of discodermolide into
the β-tubulin binding site
generated using the most
important HQSAR molecular
fragments related to
antiproliferative activity
green region encompassing the phenyl ring, indicating that
bulky para- or meta-substituents would enhance the affin-
ity. The yellow contour near the benzoxathiin reveals that
less bulky substituents attached to this ring are positively
related to the biological parameter. In addition, these results
are highly compatible with the 3D environment of the ER
binding site as demonstrated in Fig. 4c [21]. It is important to
note that the degree to which a small molecule ligand binds to
the ER active site is determined by multiple and complemen-
tary supramolecular interactions, which can be studied using
specialized 2D molecular fragments, as well as a combina-
tion of molecular modeling and 2D and 3D QSAR studies.
As shown before, the role of HQSAR in the generation
of reliable and useful QSAR models is evident, establishing
itself as a powerful medicinal chemistry tool to guide the
design of NCE candidates. However, it is extremely impor-
tant to realize that since the information obtained from the
patterns of substructural fragments is associated to essential
ligand-receptor interactions, the HQSAR method can addi-
tionally be used as a useful strategy for the understanding
of the molecular and chemical basis underlying the ligand-
induced modulation of a given macromolecular target. For
instance, in the absence of tubulin-bound discodermolide
crystal structures, we have recently employed the HQSAR
method to generate molecular recognition patterns that were
then combined with molecular modeling studies as a step
for the understanding of essential discodermolide-tubulin
interactions associated with its high antiproliferative activity
[46]. In this study, the most important individual contribu-
tions (structural fragments) to the observed activity were
inspected in order to provide a more complete interpretation
of the predictive QSAR models. The conformation-indepen-
dent HQSAR method was especially adequate, since the dis-
codermolide system is very flexible and complex. As sche-
matically shown in Fig. 5, the most important fragments
related to biological activity (positive contributions) were
selected and used for the study of the main intermolecular
interactions within the β-tubulin system. The understanding
of the structural and chemical basis for enhanced affinity and
potency is important to guide the design of new microtubule
stabilizing antimitotic agents (MSAAs).
HQSAR: from correlation to property prediction
Although the HQSAR method has traditionally been used
to develop models with internal and external consistency, as
well as predictive power, the same basic approach can be
applied in virtual screening (VS) strategies for the identifi-
cation of hits [25, 26, 47–50]. The increasing demand for the
analysis of large data sets such as those generated by com-
binatorial chemistry and high-throughput screening (HTS)
techniques has demonstrated once again the versatility and
range of applications of HQSAR. The method is particularly
suitable for the construction of 2D ligand-based pharmaco-
phores and for the rapid evaluation and prediction of large
chemical libraries. Special characteristics include speed, ver-
satility and reliability. It is well known that robust HQSAR
models have good predictive ability for compounds not
included in training sets (employed for model generation)
and, therefore, can be applied to database mining. The nov-
elty of this approach derives from the fact that it is possi-
ble to distinguish the most important structural fragments
related to biological activity and associate them to unique
2D structural characteristics, which can be found in data sets
of chemically diverse compounds. Importantly, the molec-
ular fragments selected in hologram-based models carry a
collection of 2D chemical and structural features that can
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Fig. 6 Evaluation of the
predictive ability of HQSAR
models for a series of anticancer
agents. The number of correct
predictions decreases with
increasing percentage of
fragment types that are
extrapolated
Fig. 7 Integration of HQSAR
models and virtual screening
approaches in drug design
be quantitatively translated into specific 3D ligand–protein
interactions. Moreover, the attribution of different weights to
distinguish the relative contribution of molecular fragments
is guided by experimental values (biological activity). On
the other hand, the characterization of the chemical space is
an important factor to be considered in order to define the
applicability of the constructed HQSAR models. To eval-
uate this crucial component, we have created statistically
robust HQSAR models for a set of 180 indole derivatives
presenting potent anticancer activity as a result of their abil-
ity to bind to the colchicine site and to inhibit tubulin poly-
merization (results not shown) [51–54]. Afterwards, we have
analyzed and compared a series of HQSAR prediction sta-
tistics to provide meaningful insights that can be used for
the determination of optimal cutoff values in VS procedures.
The evaluation of the external predictive ability of the mod-
els generated using different combinations of representative
test sets revealed that the number of compounds not well
predicted becomes progressively higher with the increasing
percentage of fragment types absent in the training set, which
are in fact required for external prediction, as shown in Fig. 6.
The dashed line in Fig. 6 indicates that when validated
HQSAR models are employed for the analysis of this data
set, the percentage of correct predictions is over 60% in the
cases where the fraction of extrapolated fragment types is
less than 30%. Furthermore, the models are also able to
correctly predict more than 50% of the property values
(biological activity) for compounds with a fraction of extrap-
olated fragment types higher than 30% (model calibration).
Therefore, a proper evaluation of the predictive capability
of HQSAR models is important before using them to screen
compounds in large data sets. What we have learned is that
sufficient structural variety (chemical diversity) is of funda-
mental importance for the calibration of HQSAR models to
ensure that generated molecular recognition patterns will be
able to cover the chemical space represented by the com-
pounds in different data sets.
In the proposed drug design strategy illustrated in Fig. 7,
the identified molecular recognition patterns can be com-
bined with structure-based VS. The computational analysis
can be applied to search large chemical databases to identify
novel active compounds for a given biological target. One
important aspect is to ascertain the state of the art in the inte-
gration of fragment-based methods and structure-based VS
strategies. At the end of the process, small focused libraries
can then be prioritized for further analyzes, compound syn-
thesis or acquisition, and in vitro biological evaluation.
HQSAR: pharmacokinetic studies and ADME prediction
In addition to properties such as efficacy, potency and selec-
tivity, a drug intended for use in humans should also have
an ideal balance of pharmacokinetic parameters and safety.
Because unfavorable pharmacokinetics can negatively affect
the clinical development of many otherwise promising drug
candidates, key properties such as absorption, distribution,
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Fig. 8 HQSAR
pharmacokinetic model
generation and integrated
ADME property prediction
metabolism and excretion (ADME) have been recently con-
sidered in early phases of the drug discovery process [55, 56].
This new paradigm of research has driven the need for large-
scale screening methods. In vitro and in vivo ADME assays
are lengthy, complex, and relatively expensive in terms of
resources, reagents, and detection techniques. In this regard,
a variety of useful in silico ADME models has been devel-
oped with different levels of complexity for the screening of
large data sets of compounds, creating tools that are faster,
simpler, and more cost-effective than traditional experimen-
tal procedures [56].
More recently, it has been shown that the HQSAR
patterns of substructural fragments could also be useful in
pharmacokinetic studies, in addition to more traditional
mechanism-based pharmacodynamic modeling. Figure 8
shows a general scheme of the main steps for HQSAR-based
pharmacokinetic model generation and ADME prediction.
As it can be observed, reliable HQSAR models were suc-
cessfully generated and subsequently validated for data sets
of highly diverse compounds belonging to a variety of impor-
tant therapeutic classes [57–59]. The generated substructural
patterns can be employed as ADME filters in the process of
chemical library design and VS, therefore, integrating the
study of pharmacodynamic and pharmacokinetic properties
in the identification of new lead candidates.
The high chemical diversity and distribution of the prop-
erty values covering the entire range of possible values (e.g.,
percentage of oral bioavailability or percentage of plasma
protein binding), allied to the conformation-independent
characteristics, represent unique advantages in the applica-
tion of the HQSAR method for ADME property prediction.
All compounds to be predicted (members of test sets) will
fall within the property value interval of the training set com-
pounds (i.e., process of interpolation, prediction of new val-
ues between known values), eliminating the need for often
less meaningful results of extrapolation (i.e., prediction of
new property values outside the known training set values),
which are inherently subject to greater uncertainty.
Conclusion
The drug discovery process has been steadily becoming more
information driven. QSAR methods have successfully been
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employed as useful tools for the design of new small molecule
drug candidates, ranging from enzyme inhibitors to recep-
tor ligands [19, 23, 45, 60, 61]. There has also been substan-
tial progress in fragment-based QSAR as an important tool
in drug design [20, 21, 31–42, 46, 62]. The investigations in
attempting to correlate structural or property descriptors with
the biological activity of compounds are important in the
understanding of the activity of interest based on knowledge
of the chemical structure alone. As highlighted in this per-
spective, fragment-based HQSAR, either alone or in com-
bination with conventional 3D QSAR, molecular modeling
or VS strategies, can successfully be applied to identify hits
or lead candidates against a variety of target proteins. The
fragment-based method can be applied to simplify the com-
putational analysis of ligand binding and to map out different
structural and chemical elements required for binding affinity
and biological activity. The concept of this approach involves
the principle that each unique interaction in the binding site
represented by different molecular fragments should produce
an optimized compound with binding affinity that is the sum
of the individual essential interactions. The HQSAR method
allows the investigation of a wide variety of pharmacody-
namic and pharmacokinetic properties for a high number of
both structurally related and chemically diverse compounds.
Although there are many fundamental aspects to be further
explored with HQSAR, what is clear is that these and other
advances will continue to enable and expand the application
of fragment-based QSAR in the development of new drugs
candidates as an essential ingredient of drug design, and it is
likely to remain as such for the foreseeable future.
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